Tisbury Pharmaceuticals

About

Funding history · 1 round · $32.0M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is the primary focus of Tisbury Pharmaceuticals?

Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of treatments for primary open-angle glaucoma.

What is the status of Tisbury Pharmaceuticals as of November 2019?

Tisbury Pharmaceuticals is inactive, having ceased operations in November 2019.

When was Tisbury Pharmaceuticals founded?

Tisbury Pharmaceuticals was founded in January 2017.

What is the name of Tisbury Pharmaceuticals' clinical candidate and its mechanism of action?

Tisbury Pharmaceuticals' clinical candidate is R-801, which accelerates flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation.

How much funding has Tisbury Pharmaceuticals raised in total?

Tisbury Pharmaceuticals has raised a total of $32,000,000 USD. For a full financing history, please refer to startupim.

Which investors participated in Tisbury Pharmaceuticals' Series A funding round in June 2017?

In June 2017, Tisbury Pharmaceuticals secured a Series A round with participation from investors including OrbiMed, Clarus Ventures, Pontifax, and Healthcap.

Where is Tisbury Pharmaceuticals headquartered?

Tisbury Pharmaceuticals is headquartered in Qatsrin, North District, Israel, and also has an office in Beverly, Massachusetts, United States.

Who is the founder of Tisbury Pharmaceuticals?

Andrew Salzman is identified as a founder of Tisbury Pharmaceuticals.

Sectors & technology

Tags